Compare FUND & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUND | BNTC |
|---|---|---|
| Founded | 1988 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.8M | 313.9M |
| IPO Year | N/A | 2020 |
| Metric | FUND | BNTC |
|---|---|---|
| Price | $9.75 | $8.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 16.8K | ★ 197.1K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.97 | $8.00 |
| 52 Week High | $10.99 | $16.76 |
| Indicator | FUND | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 41.76 |
| Support Level | $9.39 | $8.52 |
| Resistance Level | $10.10 | $14.09 |
| Average True Range (ATR) | 0.22 | 0.67 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 30.68 | 39.20 |
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.